Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs Recovery Delivered

Two GLP-1 desks, one scoreboard. We put ShedRx and Recovery Delivered head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 124 · Grade C

Recovery Delivered

Visit Recovery Delivered Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 71 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Recovery Delivered a bad call — it's best for readers who want cheap compounded glp-1 with an included provider video visit and fast home delivery. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
48
Supply Reliability
86
71
Transparency
84
88
Access Breadth
85
80
Clinical Oversight
85
76
Track Record
86
69
ShedRxBrief Score 87 · 71Recovery Delivered

Price, coverage & the tracker

ShedRxRecovery Delivered
Brief Score87/100 (B+)71/100 (C)
Semaglutide$199/moFrom $199/mo (starting dose, compounded)
Tirzepatide$299/moFrom $219/mo (starting dose, compounded)
CoverageNot disclosed32 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Recovery Delivered: New to the tracker on 1 August 2026. The published line reads From $199/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.